Logo image
Cytomegalovirus-targeted immunotherapy and glioblastoma: hype or hope?
Journal article   Peer reviewed

Cytomegalovirus-targeted immunotherapy and glioblastoma: hype or hope?

Sherise D. Ferguson, Visish M. Srinivasan, Michael G. Z. Ghali and Amy B. Heimberger
Immunotherapy, v 8(4), pp 413-423
01 Apr 2016
PMID: 26973123

Abstract

Immunology Life Sciences & Biomedicine Science & Technology
Malignant gliomas, including glioblastoma (GBM), are the most common primary brain tumors. Despite extensive research only modest gains have been made in long-term survival. Standard of care involves maximizing safe surgical resection followed by concurrent chemoradiation with temozolomide. Immunotherapy for GBM is an area of intense research in recent years. New immunotherapies, although promising, have not been integrated into standard practice. Human cytomegalovirus (HCMV) is a DNA virus of the family Herpesviridae. Human seroprevalence is approximately 80%, and in most cases, is associated with asymptomatic infection. HCMV may be an important agent in the initiation, promotion and/or progression of tumorigenesis. Regardless of a possible etiologic role in GBM, interest has centered on exploiting this association for development of immunomodulatory therapies.

Metrics

4 Record Views
8 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Domestic collaboration
Web of Science research areas
Immunology
Logo image